TROP2 ADC 治疗经治的 EGFR 突变患者：中位 OS 长达近 26 个月！_腾讯新闻
引言2026 年欧洲肿瘤内科学会（ESMO）大会于当地时间 2026 年 10...
Commentary: acupuncture-associated gastric mucosal repair and the EGF–EGFR-related signaling network: evidence, limitations, and prospects
We read with great interest the review by Jiang et al. (1), which summarizes the potential involvement of the epidermal growth factor (EGF)-epidermal growth A Commentary on Acupuncture-associated gastric mucosal repair and the EGF–EGFR-related signaling network: evidence, limitations, and prospects...
Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
Abstract Background: Savolitinib is an oral, potent, highly selective MET-tyrosine kinase inhibitor (TKI). Combination therapy with savolitinib and osimertinib, an epidermal growth factor receptor (EGFR)-TKI, has shown activity in patients with EGFR-mutated, advanced non-small-cell lung cancer (NSCLC) with MET overexpression,...
Targeted cystatin C testing for large negative eGFR discordance in adults with diabetes: development and external validation of a machine-learning model
BackgroundLarge negative discordance between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFR) may reveal clinically relevant rena Abstract Background: Large negative discordance between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFR) may reveal clinically relevant renal-function differences that...
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
Original Article Share on Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI TherapyAuthors: Shun Lu, M.D., Nicolas Girard, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Frances A. Shepherd, M.D., Xiaorong Dong, M.D., Ph.D., Surein Arulananda, Ph.D., Giulio Metro, M.D., +26...
Combination Therapy vs Monotherapy in EGFR-Mutated NSCLC
Combination Therapy vs Monotherapy in EGFR-Mutated NSCLC Wade T. Iams, MD, of Tennessee Oncology, says the stability of skin toxicity rates across 8.3 months of COPERNICUS follow-up, with 86% of participants still on study, gives him the most confidence in...
Severe cutaneous adverse reaction to aumolertinib plus vebreltinib in an EGFR-mutant NSCLC patient: a case report
BackgroundThe combination of aumolertinib and vebreltinib has emerged as an effective therapeutic strategy for advanced non-small cell lung cancer(NSCLC) har Abstract Background: The combination of aumolertinib and vebreltinib has emerged as an effective therapeutic strategy for advanced non-small cell lung...
Another win for novel drug, this time in EGFR-mutated lung cancer
Izalontamab brengitecan nearly doubled PFS compared with chemotherapy A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR -mutated advanced non-small cell lung cancer (NSCLC) who progressed on third-generation EGFR tyrosine kinase...
Osimertinib plus savolitinib ‘new global standard of care’ for EGFR-mutant NSCLC
Osimertinib plus savolitinib ‘new global standard of care’ for EGFR-mutant NSCLC Randomized phase 3 trial data showed osimertinib plus savolitinib significantly improved PFS in EGFR-mutant NSCLC with MET overexpression and/or amplification. The regimen also significantly improved OS. Osimertinib plus savolitinib...
Multimodal deep learning framework integrating deep radiomics, clinical features, and EGFR Status to predict growth trends of pulmonary ground-glass nodules
AbstractBackground Pulmonary ground-glass nodules (GGNs) are commonly identified in low-dose computed tomography (CT) screenings. However, their indolent growth patterns often require prolonged follow-up to differentiate benign from malignant, presenting significant challenges for clinical decision-making and patient well-being. This study aims...